Streetbeat News

Equity Actions

ROIV

Roivant Sciences' stock is trading higher following the announcement that it will be included in the S&P MidCap 400 index.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:16 am

GMDA

Gamida Cell announced the start of a restructuring process with the support of Highbridge Capital Management. This strategic move aims to streamline operations and strengthen the company's financial position. The involvement of Highbridge Capital, a well-known investment firm, suggests a significant commitment to turning around Gamida Cell's fortunes.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:09 am

IBIO

iBio, Inc. (IBIO) has announced a collaboration with AstralBio, Inc. to develop novel antibodies for treating obesity and cardiometabolic diseases. This follows iBio's recent $15 million private placement financing aimed at supporting new partnerships like the one with AstralBio.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:06 am

PLUR

Pluri Inc. has announced a 1-for-8 reverse share split, effective at the market open on April 1. This action will consolidate every eight shares of Pluri Inc. into one share, potentially affecting the stock's liquidity and market perception.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:05 am

BJRI

BJ's Restaurants, Inc. (BJRI) has engaged PW Partners, LLC to provide recommendations on cost structure and efficiencies. This collaboration comes after a cooperation agreement where PW Partners, owning over 5% of BJRI's stock, withdrew its director nominees for the 2024 annual meeting.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:03 am

DTIL

Precision Biosciences reported a 2023 cash and cash equivalents total of $116.7M. The company also received $50M from TG Therapeutics and Caribou, along with a $40M capital raise. These funds are expected to extend the company's cash runway into the second half of 2026.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 10:59 am

KMB

Kimberly-Clark announces a strategic overhaul aiming for over $3B in gross productivity savings and $500M in working capital savings. The company targets organic net sales growth ahead of market growth and adjusted EPS growth in mid-to-high single digits. Additionally, it commits to a 100% natural forest-free ambition across its product portfolio.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 10:57 am

LE

Lands' End has provided its financial outlook for FY24, expecting revenue to range between $1.33B and $1.45B, which is slightly below the $1.46B estimate. The company also projects its adjusted earnings per share (EPS) to be between $0.10 and $0.38, significantly surpassing the estimated $(1.9).

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 10:56 am

CLRB

Cellectar Biosciences announced that its cash and cash equivalents of $9.6M, along with $22.9M generated from exercised warrants in 2023, are expected to extend its cash runway into Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 10:52 am

INTZ

HC Wainwright & Co. analyst Scott Buck maintains a Neutral rating on Intrusion (NASDAQ:INTZ), adjusting the price target to $3 from $0.5, accounting for a 1:20 reverse stock split.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 10:17 am